Journal article
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
Abstract
Background:The Notch signalling pathway has been implicated in tumour initiation, progression, angiogenesis and development of resistance to vascular endothelial growth factor (VEGF) targeting, providing a rationale for the combination of RO4929097, a γ-secretase inhibitor, and cediranib, a VEGF receptor tyrosine kinase inhibitor.Methods:Patients received escalating doses of RO4929097 (on a 3 days-on and 4 days-off schedule) in combination with …
Authors
Sahebjam S; Bedard PL; Castonguay V; Chen Z; Reedijk M; Liu G; Cohen B; Zhang W-J; Clarke B; Zhang T
Journal
British Journal of Cancer, Vol. 109, No. 4, pp. 943–949
Publisher
Springer Nature
Publication Date
August 2013
DOI
10.1038/bjc.2013.380
ISSN
0007-0920
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzazepinesBreast NeoplasmsCarcinoma, NeuroendocrineCarcinoma, Renal CellColorectal NeoplasmsFemaleHumansKidney NeoplasmsLeiomyosarcomaMaleMiddle AgedNeoplasmsQuinazolinesSarcoma, Endometrial StromalThyroid NeoplasmsTreatment OutcomeUterine NeoplasmsYoung Adult